Publication | Closed Access

Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro

Tissue EngineeringCollagenase ProductionFibrosisImmunologyPathologyPersistent NormalizationWound HealingShort-term Keloid TreatmentMatrix BiologyMedicineCell BiologyHuman TissueFibroblast BiologyExtracellular MatrixConnective Tissue Disease